Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

29. Mai 2018 09:18 ET | Quelle: BioNTech AG

BioNTech Appoints Dr. Özlem Türeci as Chief Medical Officer

MAINZ, Germany, May 29, 2018 (GLOBE NEWSWIRE) -- BioNTech AG, a fully-integrated biotechnology company pioneering individualized cancer immunotherapy, today announced the appointment of Özlem...
04. Januar 2018 02:30 ET | Quelle: BioNTech AG

BioNTech schließt Serie A Finanzierung über USD 270 Millionen ab

Mainz, Jan. 04, 2018 (GLOBE NEWSWIRE) -- Die BioNTech AG, ein vollständig integriertes Biotechnologieunternehmen und Wegbereiter der individualisierten Krebsimmuntherapie, gab heute den Abschluss...
04. Januar 2018 02:30 ET | Quelle: BioNTech AG

BioNTech Secures USD 270 Million in Series A Financing

MAINZ, Germany, Jan. 04, 2018 (GLOBE NEWSWIRE) -- BioNTech AG, a fully-integrated biotechnology company pioneering individualized cancer immunotherapy, today announced it has completed a USD 270...
06. September 2017 02:00 ET | Quelle: BioNTech AG

BioNTech AG Enters into Licensing Agreement with CELLSCRIPT, LLC as it Advances Development of Messenger RNA Encoding Bispecific Antibodies and other Therapeutic Proteins

MAINZ, Germany, Sept. 06, 2017 (GLOBE NEWSWIRE) -- BioNTech AG, a fully integrated biotechnology company pioneering individualized cancer immunotherapy, today announced that it has entered into a...
05. Juli 2017 13:01 ET | Quelle: BioNTech AG

Nature Publication Reports Favorable Clinical Trial Results of BioNTech's Individualized Cancer Vaccine IVAC® MUTANOME

MAINZ, Germany, July 05, 2017 (GLOBE NEWSWIRE) -- BioNTech AG, a fully-integrated biotechnology company pioneering individualized cancer immunotherapy, today announced Phase I trial results...
12. Juni 2017 11:01 ET | Quelle: BioNTech AG

Nature Medicine Reports Elimination of Large Tumors in Mice by Messenger RNA-Encoded Bispecific Antibodies

MAINZ, Germany, June 12, 2017 (GLOBE NEWSWIRE) -- BioNTech AG, a fully-integrated biotechnology company pioneering individualized cancer immunotherapy, reported preclinical data featuring a novel...
12. Juni 2017 11:01 ET | Quelle: BioNTech AG

NATURE MEDICINE BERICHTET ÜBER ELIMINIERUNG GROßER TUMORE BEI MÄUSEN DURCH MESSENGER-RNA, DIE FÜR BISPEZIFISCHE ANTIKÖRPER KODIERT

Mainz, June 12, 2017 (GLOBE NEWSWIRE) -- Die BioNTech AG, ein vollintegriertes Biotechnologieunternehmen, das personalisierte Krebsimmuntherapien entwickelt, gab heute präklinische Daten zu einer...
12. Juni 2017 11:01 ET | Quelle: BioNTech AG

Nature Medicine Reports Elimination of Large Tumors in Mice by Messenger RNA-Encoded Bispecific Antibodies

MAINZ, Germany, June 12, 2017 (GLOBE NEWSWIRE) -- BioNTech AG, a fully-integrated biotechnology company pioneering individualized cancer immunotherapy, reported preclinical data featuring a novel...
07. März 2017 04:00 ET | Quelle: BioNTech AG

BioNTech to Present Interim Phase I/II Data for Investigational mRNA Vaccine in Melanoma Patients at AACR Annual Meeting 2017

MAINZ, Germany, March 07, 2017 (GLOBE NEWSWIRE) -- BioNTech AG, a fully-integrated biotechnology company pioneering individualized cancer immunotherapy, today announced that it will present interim...
22. Februar 2017 02:00 ET | Quelle: BioNTech AG

BioNTech to Present at Cowen and Company’s 37th Annual Health Care Conference

MAINZ, Germany, Feb. 22, 2017 (GLOBE NEWSWIRE) -- BioNTech AG, a fully integrated biotechnology company pioneering individualized cancer immunotherapy, today announced that Sean Marett, COO of...

Vorherige Seite